WallStreetZenWallStreetZen

NASDAQ: YMAB
Y Mabs Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

YMAB past revenue growth

How has YMAB's revenue growth performed historically?
Company
29.96%
Industry
149.51%
Market
17.15%
YMAB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
YMAB's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
YMAB's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

YMAB earnings and revenue history

Current Revenue
$84.8M
Current Earnings
-$21.4M
Current Profit Margin
-25.3%

YMAB Return on Equity

Current Company
-20.7%
Current Industry
-63.5%
Current Market
188%
YMAB's Return on Equity (-20.7%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when YMAB announces earnings.

YMAB Return on Assets

Current Company
-16.3%
Current Industry
2.9%
YMAB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

YMAB Return on Capital Employed

Current Company
-23.83%
Current Industry
19.5%
YMAB has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

YMAB vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
YMAB$84.82M-$24.94M-$21.43M+145.62%N/A
SVRA$0.00-$50.09M-$54.70M-100.00%N/A
NRIX$80.89M-$130.28M-$144.73M+145.04%N/A
PHAR$266.65M$4.25M-$11.47M+11.91%N/A
CGEM$0.00-$166.97M-$153.16M-100.00%N/A
View Top Biotech Stocks

YMAB earnings dates

Next earnings date
May 6, 2024

Y Mabs Therapeutics Earnings & Revenue FAQ

What were YMAB's earnings last quarter?

On Invalid Date, Y Mabs Therapeutics (NASDAQ: YMAB) reported Q4 2023 earnings per share (EPS) of -$0.02, up 200% year over year. Total Y Mabs Therapeutics earnings for the quarter were -$988.00 thousand. In the same quarter last year, Y Mabs Therapeutics's earnings per share (EPS) was $0.02.

If you're new to stock investing, here's how to buy Y Mabs Therapeutics stock.

What was YMAB's earnings growth in the past year?

As of Q2 2024, Y Mabs Therapeutics's earnings has grown year over year. Y Mabs Therapeutics's earnings in the past year totalled -$21.43 million.

What is YMAB's earnings date?

Y Mabs Therapeutics's earnings date is Invalid Date. Add YMAB to your watchlist to be reminded of YMAB's next earnings announcement.

What was YMAB's revenue last quarter?

On Invalid Date, Y Mabs Therapeutics (NASDAQ: YMAB) reported Q4 2023 revenue of $23.36 million up 25.71% year over year. In the same quarter last year, Y Mabs Therapeutics's revenue was $31.45 million.

What was YMAB's revenue growth in the past year?

As of Q2 2024, Y Mabs Therapeutics's revenue has grown 29.96% year over year. This is 119.56 percentage points lower than the US Biotechnology industry revenue growth rate of 149.51%. Y Mabs Therapeutics's revenue in the past year totalled $84.82 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.